Skip to main content

Advertisement

Table 1 Subject characteristics

From: Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease

N 210
Age ─ years 70.6 ± 8.7
Male sex ─ no. (%) 136 (64.7)
Morphometric findings  
 Body mass index ─ kg/m2 24.6 ± 4.1
 Waist circumference ─ cm 88.6 ± 10.5
Blood pressure  
 Systolic ─ mmHg 133.5 ± 19.6
 Diastolic ─ mmHg 73.9 ± 13.5
Laboratory measurements  
 Serum creatinine ─ mg/dL 0.9 ± 0.2
 Total cholesterol ─ mg/dL 166.4 ± 31.7
 Triglycerides ─ mg/dL  
  Median (interquartile range) 105 (77–143)
 HDL cholesterol ─ mg/dL 50.1 ± 13.7
 LDL cholesterol ─ mg/dL 92.6 ± 23.0
 MDA-LDL ─ U/L 99.0 ± 39.0
 Hemoglobin A1c ─ % 6.9 ± 1.0
 Adiponectin ─ μg/dL  
  Median (interquartile range) 13.3 (8.5 − 24.1)
Current medications ─ no. (%)  
 Statins 210 (100)
 ACE-Is/ARBs 152 (72.4)
 β-Blockers 132 (62.9)
 Ca channel blockers 85 (40.5)
 Metformin 84 (40.0)
 Pioglitazone 79 (37.6)
 α-Glucosidase inhibitors 70 (33.3)
 Sulfonylurea 61 (29.0)
 Insulin therapy 37 (17.6)
 Phenylalanine derivatives 14 (6.7)
 DPP4 inhibitors 15 (7.1)
 EPA 9 (4.3)
 Ezetimibe 1 (0.5)
  1. Values represent means ± SD unless indicated otherwise.
  2. Abbreviations: ARB angiotensin II receptor blocker, ACE-I angiotensin-converting enzyme inhibitor, DPP4 dipeptidyl peptidase-4; EPA eicosapentaenoic acid, HDL high-density lipoprotein, LDL low-density lipoprotein, MDA-LDL malondialdehyde-modified LDL.